头孢丙烯在下呼吸道细菌感染患者的药代动力学研究
The pharmacokinetics study of cefprozil in patients with low respiratory tract bacterial infections
-
摘要: 目的 :通过研究下呼吸道细菌感染患者的头孢丙烯临床药代动力学参数,为临床选择合理给药方案提供依据。 方法 :用HPLC法测定10例下呼吸道细菌感染患者连续给药5d后的稳态血药浓度,数据用3P97 药物动力学模拟系统处理。 结果 :头孢丙烯的药时曲线符合二室开放模型,主要药代动力学参数:t1/2为 (1.55±0.17)h,MRT为(2.52±0.15)h,Cmax为(13.32±1.28)μg／mL,tmax为(1.41±0.31)h,AUC0-10为 (31.68±7.68)μg h／mL。 结论 :口服头孢丙烯片500mg,每天2次,能获得控制下呼吸道细菌感染的有效治疗浓度。Abstract: Objective :To offer the evidence for reasonable dosage regimen by the pharmacokinetics study of cefprozil in patients with low respiratory tract bacterial infections. Methods :The cefprozil concentration in plasma was determined by the high performance liquid chromatography method. The pharmacokinetic parameters were obtained by using 3P97 imitate program. Results :With oral multiple - dose of 500mg of cefprozil twice over 5 consecutive days, the main pharmacokinetic parameters obtained from the patients were as follows :t1/2 was (1.55±0.17)h,MRT was (2.52 ±0. 15)h.Cmax was ( 13.32 ± 1. 28)μg/mL,tmax was (1.41±0.31)h,AUC0-10 was (31.68 ±7.68)μg·h/mL. Conclusions :Cefprozil 500mg, bid orally may be effective against low respiratory tract bacterial infections.
-
Key words:
- cefprozil /
- pharmacokinetics /
- HPLC /
- low respiratory tract bacterial infections
-
点击查看大图
计量
- 文章访问数: 2064
- HTML全文浏览量: 238
- PDF下载量: 227
- 被引次数: 0
下载:
